We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

168 hedge funds and large institutions have $1.24B invested in Arcutis Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 52 increasing their positions, 40 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more funds holding in top 10

Funds holding in top 10: 1 → 6 (+5)

257% more capital invested

Capital invested by funds: $347M → $1.24B (+$892M)

157% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 23

30% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 40

26% more funds holding

Funds holding: 133 → 168 (+35)

5.04% less ownership

Funds ownership: 113.75% → 108.71% (-5%)

42% less call options, than puts

Call options by funds: $6.39M | Put options by funds: $11.1M

Holders
168
Holders Change
+35
Holders Change %
+26.32%
% of All Funds
2.42%
Holding in Top 10
6
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+500%
% of All Funds
0.09%
New
59
Increased
52
Reduced
40
Closed
23
Calls
$6.39M
Puts
$11.1M
Net Calls
-$4.68M
Net Calls Change
-$4.68M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$54.2M
2
GGHC
Gilder Gagnon Howe & Co
New York
+$31.6M
3
Jennison Associates
Jennison Associates
New York
+$23.2M
4
CAM
Cormorant Asset Management
Massachusetts
+$15.9M
5
Citadel Advisors
Citadel Advisors
Florida
+$14.3M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$60.9M
2
Millennium Management
Millennium Management
New York
-$16.3M
3
VPC
Vestal Point Capital
New York
-$8.72M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.07M
5
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$7.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
51
Two Sigma Advisers
New York
$3.28M +$2.47M +330,900 New
PP
52
PDT Partners
New York
$3.17M +$2.39M +320,226 New
Bank of New York Mellon
53
Bank of New York Mellon
New York
$3.07M -$58.2K -7,803 -2%
N
54
Nuveen
North Carolina
$2.46M +$256K +34,351 +16%
Hudson Bay Capital Management
55
Hudson Bay Capital Management
Connecticut
$2.23M +$1.68M +225,000 New
SCM
56
Soleus Capital Management
Connecticut
$2.23M +$1.68M +225,000 New
JAFL
57
Jay A. Fishman Ltd
Michigan
$2.22M +$1.28M +171,300 +323%
ECM
58
ExodusPoint Capital Management
New York
$2.2M +$1.66M +222,222 New
D.E. Shaw & Co
59
D.E. Shaw & Co
New York
$2.15M +$1.62M +216,866 New
Jane Street
60
Jane Street
New York
$2.12M +$395K +52,935 +33%
Squarepoint
61
Squarepoint
New York
$2.04M +$421K +56,447 +38%
Tudor Investment Corp
62
Tudor Investment Corp
Connecticut
$2.03M +$1.53M +204,779 New
Norges Bank
63
Norges Bank
Norway
$1.73M +$700K +93,808 +116%
BFM
64
Boothbay Fund Management
New York
$1.7M +$1.28M +171,796 New
PI
65
Pennant Investors
New Jersey
$1.69M – – –
LPL Financial
66
LPL Financial
California
$1.57M -$235K -31,438 -17%
Aberdeen Group
67
Aberdeen Group
United Kingdom
$1.48M – – –
Los Angeles Capital Management
68
Los Angeles Capital Management
California
$1.47M -$344K -46,028 -24%
Fidelity Investments
69
Fidelity Investments
Massachusetts
$1.4M -$8.07M -1,081,306 -88%
CCM
70
Cinctive Capital Management
New York
$1.38M +$1.04M +139,211 New
DekaBank Deutsche Girozentrale
71
DekaBank Deutsche Girozentrale
Germany
$1.34M – – –
PA
72
Profund Advisors
Maryland
$1.25M +$942K +126,283 New
RhumbLine Advisers
73
RhumbLine Advisers
Massachusetts
$1.24M +$137K +18,402 +17%
SFI
74
Susquehanna Fundamental Investments
Pennsylvania
$1.19M +$899K +120,493 New
Susquehanna International Group
75
Susquehanna International Group
Pennsylvania
$993K -$1.71M -228,656 -70%
1 2
3
4 5

ARQT Hedge Fund Activity: Q1 2024 in Review

168 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2024, worth a combined $1.24B — up 257% from $347M a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new ARQT positions and 23 closed out — a net gain of 36 holders — while 52 added to existing stakes and 40 trimmed.

The largest buyer was State Street, adding an estimated $54.2M. The largest seller was Morgan Stanley, cutting an estimated $60.9M.

  • 168 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2024, up from 133 in Q4 2023.
  • Funds reported $1.24B of Arcutis Biotherapeutics stock for Q1 2024, up 257% quarter-over-quarter.
  • 59 funds opened new Arcutis Biotherapeutics positions in Q1 2024 and 23 closed out, a net change of +36 holders.
  • The largest Arcutis Biotherapeutics buyer in Q1 2024 was State Street, an estimated $54.2M added.
  • The largest Arcutis Biotherapeutics seller in Q1 2024 was Morgan Stanley, an estimated $60.9M sold.

Based on aggregated 13F filings for Q1 2024.